NASDAQ:AMRX Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis $21.38 +0.10 (+0.47%) Closing price 04:00 PM EasternExtended Trading$21.36 -0.02 (-0.09%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amneal Pharmaceuticals Stock (NASDAQ:AMRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amneal Pharmaceuticals alerts:Sign Up Key Stats Today's Range$21.03▼$21.6350-Day Range$16.65▼$21.5152-Week Range$11.39▼$21.68Volume2.36 million shsAverage Volume2.46 million shsMarket Capitalization$6.83 billionP/E Ratio50.90Dividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company Overview Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets. Founded in 2002 by brothers Chirag and Chintu Patel, Amneal became a larger pharmaceutical company following its 2018 combination with Impax Laboratories. It is headquartered in Bridgewater, New Jersey.AI Generated. May Contain Errors. Read More Amneal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreAMRX MarketRank™: 3.14875581077 of 5 starsAmneal Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 302nd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmneal Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amneal Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth16.84% Earnings GrowthEarnings for Amneal Pharmaceuticals are expected to grow by 16.84% in the coming year, from $0.95 to $1.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amneal Pharmaceuticals is 50.90, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Amneal Pharmaceuticals is 50.90, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.10.Price to Earnings Growth RatioAmneal Pharmaceuticals has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmneal Pharmaceuticals has a P/B Ratio of 12.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.33% of the float of Amneal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmneal Pharmaceuticals has a short interest ratio ("days to cover") of 3.69, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amneal Pharmaceuticals has recently increased by 24.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmneal Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmneal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.86 News SentimentAmneal Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,216,567.00 in company stock.Percentage Held by Insiders17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.82% of the stock of Amneal Pharmaceuticals is held by institutions.Read more about Amneal Pharmaceuticals' insider trading history. Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRX Stock News HeadlinesAmneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers3 hours ago | globenewswire.comAmneal Pharmaceuticals (AMRX) Lifts 2026 Guidance, Is The Upside Already Priced In?November 8 at 9:00 AM | finance.yahoo.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.November 10 at 1:00 AM | Weiss Ratings (Ad)Should Raised 2026 Guidance Require Action From Amneal Pharmaceuticals (AMRX) Investors?November 5, 2026 | uk.finance.yahoo.comAMRX Q3 deep dive: Biosimilars and specialty launches expand growth engines, guidance raisedNovember 4, 2026 | msn.comAmneal Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 4, 2026 | seekingalpha.comAmneal Pharmaceuticals, Inc. Announces Unaudited Asset Impairment Charges for Three Months Ended September 30, 2026November 3, 2026 | marketscreener.comMAmneal (NASDAQ: AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectationsNovember 3, 2026 | msn.comSee More Headlines AMRX Stock Analysis - Frequently Asked Questions How have AMRX shares performed this year? Amneal Pharmaceuticals' stock was trading at $12.60 on January 1st, 2026. Since then, AMRX stock has increased by 69.7% and is now trading at $21.38. How were Amneal Pharmaceuticals' earnings last quarter? Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) released its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.23 by $0.03. The business had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a trailing twelve-month return on equity of 283.50%. Read the conference call transcript. Who are Amneal Pharmaceuticals' major shareholders? Top institutional investors of Amneal Pharmaceuticals include Allspring Global Investments Holdings LLC (1.20%), Assenagon Asset Management S.A. (0.63%), Congress Asset Management Co. (0.48%) and Public Sector Pension Investment Board (0.32%). Insiders that own company stock include Tushar Bhikhubhai Patel, Gautam Patel, Ted C Nark, Nikita Shah, John Kiely, Andrew S Boyer, Deborah M Autor and Jason B Daly. View institutional ownership trends. How do I buy shares of Amneal Pharmaceuticals? Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amneal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Tesla (TSLA), NIO (NIO), Palantir Technologies (PLTR) and Pfizer (PFE). Company Calendar Last Earnings11/03/2026Today11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AMRX's financial health is in the Green zone, according to TradeSmith. AMRX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMRX Previous SymbolNASDAQ:AMRX CIK1723128 Webamneal.com Phone908-947-3120Fax908-947-3146Employees8,500Year Founded2002Price Target and Rating Average Price Target for Amneal Pharmaceuticals$23.00 High Price Target$27.00 Low Price Target$17.00 Potential Upside/Downside+7.6%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.42 Trailing P/E Ratio50.90 Forward P/E Ratio19.26 P/E Growth2.33Net Income$72.06 million Net Margins4.17% Pretax Margin6.93% Return on Equity283.50% Return on Assets7.79% Debt Debt-to-Equity Ratio5.61 Current Ratio1.87 Quick Ratio1.44 Sales & Book Value Annual Sales$3.02 billion Price / Sales2.26 Cash Flow$1.67 per share Price / Cash Flow12.78 Book Value$1.66 per share Price / Book12.88Miscellaneous Outstanding Shares319,350,000Free Float264,106,000Market Cap$6.83 billion OptionableOptionable Beta1.24 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:AMRX) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredIt’s now or neverAnthropic's Claude now generates more revenue than ChatGPT, and the company is about to go public at a $1.5 tr...Paradigm Press | SponsoredThe One AI Stock to Watch in 2027In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 700 percent. Now he's...Prosperity Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
